Thelansis

  Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to affect the prognosis of CRC in men adversely. About a quarter of a contributor to genetic predisposition. The development time of CRC usually lasts from several to several years; therefore, it is essential to diagnose it early in developing the disease. Previously diagnosed with cancer, a history of colon polyps, inflammatory bowel diseases, diabetes mellitus, or cholecystectomy may lead to colorectal cancer (CRC). Surgery encompasses the primary form of treatment for colon cancer, whereas chemotherapy is used most commonly in the adjuvant setting. The 5-year overall survival for patients with localized, regional, and metastatic colon cancer is 91%, 72%, and 13%. Clinical outcomes in mCRC have improved significa...